Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Novoheart Holdings

DB:3NH
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3NH
DB
CA$83M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Novoheart Holdings has significant price volatility in the past 3 months.
3NH Share Price and Events
7 Day Returns
4.2%
DB:3NH
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
0%
DB:3NH
-7.4%
DE Biotechs
-14.2%
DE Market
3NH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Novoheart Holdings (3NH) 4.2% -26.5% -20.8% 0% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 3NH outperformed the Biotechs industry which returned -7.4% over the past year.
  • 3NH outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
3NH
Industry
5yr Volatility vs Market

3NH Value

 Is Novoheart Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Novoheart Holdings. This is due to cash flow or dividend data being unavailable. The share price is €0.297.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Novoheart Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Novoheart Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3NH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.04
TSXV:NVH Share Price ** TSXV (2020-04-08) in CAD CA$0.44
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Novoheart Holdings.

DB:3NH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:NVH Share Price ÷ EPS (both in CAD)

= 0.44 ÷ -0.04

-10.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novoheart Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Novoheart Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Novoheart Holdings's expected growth come at a high price?
Raw Data
DB:3NH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Novoheart Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Novoheart Holdings's assets?
Raw Data
DB:3NH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.14
TSXV:NVH Share Price * TSXV (2020-04-08) in CAD CA$0.44
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:3NH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:NVH Share Price ÷ Book Value per Share (both in CAD)

= 0.44 ÷ 0.14

3.15x

* Primary Listing of Novoheart Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novoheart Holdings is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Novoheart Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Novoheart Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

3NH Future Performance

 How is Novoheart Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novoheart Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Novoheart Holdings expected to grow at an attractive rate?
  • Unable to compare Novoheart Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Novoheart Holdings's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Novoheart Holdings's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:3NH Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3NH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3NH Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -8 -8
2019-09-30 0 -4 -7
2019-06-30 0 -3 -8
2019-03-31 0 -3 -8
2018-12-31 0 -4 -8
2018-09-30 0 -5 -8
2018-06-30 0 -5 -12
2018-03-31 0 -5 -10
2017-12-31 -3 -9
2017-09-30 -3 -8
2017-06-30 -3 -3
2017-03-31 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Novoheart Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Novoheart Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3NH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Novoheart Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3NH Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.04
2019-09-30 -0.06
2019-06-30 -0.08
2019-03-31 -0.09
2018-12-31 -0.09
2018-09-30 -0.09
2018-06-30 -0.17
2018-03-31 -0.20
2017-12-31 -0.33
2017-09-30 -1.08
2017-06-30 -0.51
2017-03-31 -0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Novoheart Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Novoheart Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Novoheart Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Novoheart Holdings's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Novoheart Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Novoheart Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

3NH Past Performance

  How has Novoheart Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Novoheart Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Novoheart Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Novoheart Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Novoheart Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Novoheart Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Novoheart Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3NH Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.53 -7.99 5.33 2.89
2019-09-30 0.34 -7.16 4.84 2.42
2019-06-30 0.17 -7.66 5.24 2.18
2019-03-31 0.19 -8.02 5.84 1.88
2018-12-31 0.10 -8.43 5.89 1.72
2018-09-30 0.10 -8.14 5.65 1.74
2018-06-30 0.10 -12.46 4.78 1.65
2018-03-31 0.02 -10.19 3.23 1.24
2017-12-31 -9.37 2.51 1.24
2017-09-30 -8.49 1.83 1.16
2017-06-30 -2.65 1.49 1.15
2017-03-31 -2.59 1.13 1.39
2016-06-30 -1.15 0.38 0.75
2015-06-30 -0.44 0.32 0.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Novoheart Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Novoheart Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Novoheart Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Novoheart Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Novoheart Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

3NH Health

 How is Novoheart Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Novoheart Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Novoheart Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Novoheart Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Novoheart Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Novoheart Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Novoheart Holdings Company Filings, last reported 3 months ago.

DB:3NH Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 26.39 0.00 12.42
2019-09-30 28.98 0.00 19.96
2019-06-30 30.10 1.68 18.50
2019-03-31 -1.41 0.85 0.83
2018-12-31 -0.42 0.00 0.73
2018-09-30 1.21 0.00 0.57
2018-06-30 2.51 0.00 1.81
2018-03-31 4.66 0.00 2.91
2017-12-31 5.94 0.00 4.93
2017-09-30 7.32 0.00 7.15
2017-06-30 1.70 0.00 1.36
2017-03-31 0.64 0.00 0.49
2016-06-30 2.25 0.00 2.49
2015-06-30 0.60 0.00 0.21
  • Novoheart Holdings has no debt.
  • Novoheart Holdings currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Novoheart Holdings has sufficient cash runway for 1.5 years based on current free cash flow.
  • Novoheart Holdings has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 26.3% each year.
X
Financial health checks
We assess Novoheart Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Novoheart Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

3NH Dividends

 What is Novoheart Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Novoheart Holdings dividends.
If you bought €2,000 of Novoheart Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Novoheart Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Novoheart Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3NH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Novoheart Holdings has not reported any payouts.
  • Unable to verify if Novoheart Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Novoheart Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Novoheart Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Novoheart Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Novoheart Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Novoheart Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

3NH Management

 What is the CEO of Novoheart Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ronald Li
COMPENSATION CA$295,168
AGE 48
TENURE AS CEO 4.3 years
CEO Bio

Dr. Ronald Li Sc.(Hons), Ph.D., is Scientific Co-Founder at Novoheart Holdings Ltd. and also has been its Chief Executive Officer since 2016 and has served as a Director since September 27, 2017. Dr. Li serves as the President and Chief Executive Officer of Novoheart Limited, a Hong Kong based bio-medical technology company. He is concurrently Director of Ming-Wai Lau Centre for Reparative Medicine, Karolinska Institutet (KI), Hong Kong node, Director and Endowed Professor of Stem Cell & Regenerative Medicine at Hong Kong University, Co-Director and Professor of Section of Cardiac Tissue & Cell Engineering, Mount Sinai School of Medicine. He started his career as Assistant Professor of Cardiology, and Cellular and Molecular Medicine at the Johns Hopkins University (JHU) School of Medicine. He founded and led the Human Embryonic Stem Cell Consortium when he was recruited in 2005 to become a tenured Associate Professor at the University of California, Davis. Prof. Li also co-directed the Section of Cardiovascular Cell & Tissue Engineering in Icahn School of Medicine at Mount Sinai with Prof. Kevin Costa. Prof. Li has received multiple accolades and recognitions during his career, including the Spirit of Hong Kong Innovating for Good Award by the South China Morning Post (2015), the Top Young Faculty Award (2002, 2004), the Top Prize for the Young Investigator Basic Research (2001) and Top Postdoctoral Fellow Helen Taussig Award (2001) of JHU School of Medicine, Young Investigator Award 1st Prize from the Heart Rhythm Society (2002), and the Career Development Award from the Cardiac Arrhythmias Research & Education Foundation (2001). He is a Professor of Cardiology. He has been Director at Woodrose Ventures Corporation since March 15, 2017. Prof. Li graduated with his B.S. with honors in Biotechnology from University of Waterloo, Ontario, on Dean’s List and his Ph.D. in Cardiology/Physiology at the University of Toronto.

CEO Compensation
  • Ronald's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Ronald's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Novoheart Holdings management team in years:

1.6
Average Tenure
48
Average Age
  • The average tenure for the Novoheart Holdings management team is less than 2 years, this suggests a new team.
Management Team

Ronald Li

TITLE
Scientific Co-Founder
COMPENSATION
CA$295K
AGE
48
TENURE
4.3 yrs

Camie Chan

TITLE
Interim CFO
COMPENSATION
CA$312K
AGE
45
TENURE
0.4 yrs

Bernard Fermini

TITLE
Chief Research & Development Officer
COMPENSATION
CA$290K
TENURE
1.6 yrs

Kevin Costa

TITLE
Chief Scientific Officer & Scientific Co-Founder
COMPENSATION
CA$456K
AGE
53

Michelle Khine

TITLE
Scientific Co-Founder & Member of Scientific Advisory Board
Board of Directors Tenure

Average tenure and age of the Novoheart Holdings board of directors in years:

2.6
Average Tenure
48
Average Age
  • The average tenure for the Novoheart Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Allen Ma

TITLE
Independent Chairman of the Board
COMPENSATION
CA$20K
AGE
66
TENURE
2.6 yrs

Ronald Li

TITLE
Scientific Co-Founder
COMPENSATION
CA$295K
AGE
48
TENURE
2.6 yrs

Katherine Ying

TITLE
Deputy Chair of the Board
COMPENSATION
CA$14K

Camie Chan

TITLE
Interim CFO
COMPENSATION
CA$312K
AGE
45
TENURE
2.6 yrs

Michelle Khine

TITLE
Scientific Co-Founder & Member of Scientific Advisory Board

Victor Chang

TITLE
Independent Director
COMPENSATION
CA$13K
AGE
48
TENURE
2.6 yrs

James Topham

TITLE
Independent Director
COMPENSATION
CA$14K
AGE
68
TENURE
2.6 yrs

Ricky Chiu

TITLE
Independent Director
COMPENSATION
CA$11K
AGE
48
TENURE
2.6 yrs

Gordon Tomaselli

TITLE
Member of Scientific Advisory Board

Leslie Tung

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Dec 19 Buy Ngan Ng Yu Ying Individual 13. Dec 19 13. Dec 19 79,000 €0.36 €28,514
12. Dec 19 Buy Ngan Ng Yu Ying Individual 10. Dec 19 12. Dec 19 143,000 €0.34 €47,011
09. Dec 19 Buy Ngan Ng Yu Ying Individual 09. Dec 19 09. Dec 19 60,000 €0.32 €19,255
23. Oct 19 Buy Ngan Ng Yu Ying Individual 30. Sep 19 30. Sep 19 67,500 €0.20 €13,813
07. Dec 19 Buy Ngan Ng Yu Ying Individual 06. Dec 19 06. Dec 19 72,500 €0.31 €21,916
03. Jul 19 Buy Marine Bridge International Limited Company 28. Jun 19 28. Jun 19 6,447,286 €0.24 €1,574,490
02. Jul 19 Buy New Bioera Holdings Limited Company 28. Jun 19 28. Jun 19 37,200,000 €0.24 €9,084,602
X
Management checks
We assess Novoheart Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Novoheart Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

3NH News

Simply Wall St News

3NH Company Info

Description

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

Details
Name: Novoheart Holdings Inc.
3NH
Exchange: DB
Founded:
CA$54,517,691
188,640,774
Website: http://www.novoheart.com
Address: Novoheart Holdings Inc.
595 Burrard Street,
Suite 2600,
Vancouver,
British Columbia, V7X 1L3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV NVH New Common Shares TSX Venture Exchange CA CAD 04. Oct 2017
OTCPK PFRC.F New Common Shares Pink Sheets LLC US USD 04. Oct 2017
DB 3NH New Common Shares Deutsche Boerse AG DE EUR 04. Oct 2017
Number of employees
Current staff
Staff numbers
0
Novoheart Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:11
End of day share price update: 2020/04/08 00:00
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.